- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Toll-Like Receptors for Cancer Therapy
Authors
Keywords
-
Journal
Targeted Oncology
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-19
DOI
10.1007/s11523-018-0589-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A multiprotein supercomplex controlling oncogenic signalling in lymphoma
- (2018) James D. Phelan et al. NATURE
- Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy
- (2018) Petr O. Ilyinskii et al. PLoS One
- Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer
- (2018) Ippokratis Messaritakis et al. PLoS One
- The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression
- (2018) Smruti Pushalkar et al. Cancer Discovery
- Abstract 2563: Macrophage Toll-like receptor-chimeric antigen receptors (MOTO-CARs) as a novel adoptive cell therapy for the treatment of solid malignancies
- (2018) Edwin J. Velazquez et al. CANCER RESEARCH
- Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword
- (2017) Marion Dajon et al. IMMUNOBIOLOGY
- Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer
- (2017) Satoshi Okazaki et al. INTERNATIONAL JOURNAL OF CANCER
- Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells
- (2017) Sarang Tartey et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells
- (2017) Y Lai et al. LEUKEMIA
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Toll-like receptor 2 induces adenosine receptor A2a and promotes human squamous carcinoma cell growth via extracellular signal regulated kinases ½
- (2017) Chithra Devi Palani et al. Oncotarget
- A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy
- (2017) Yohei Takeda et al. Cell Reports
- Research progress in the treatment of small cell lung cancer
- (2017) Yan-fang Qiu et al. Journal of Cancer
- Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases
- (2017) Lupe G. Salazar et al. JAMA Oncology
- A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer
- (2017) Patrick M. Dillon et al. Journal for ImmunoTherapy of Cancer
- Toll-like receptor signaling in colorectal cancer: Carcinogenesis to cancer therapy
- (2017) Ting-Ting Li et al. WORLD JOURNAL OF GASTROENTEROLOGY
- The critical role of toll-like receptors — From microbial recognition to autoimmunity: A comprehensive review
- (2016) Maximiliano Javier Jiménez-Dalmaroni et al. AUTOIMMUNITY REVIEWS
- Sensing danger: toll-like receptors and outcome in allogeneic hematopoietic stem cell transplantation
- (2016) B Kornblit et al. BONE MARROW TRANSPLANTATION
- Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases
- (2016) Ileana S. Mauldin et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Blockade of high mobility group box 1 augments antitumor T-cell response induced by peptide vaccination as a co-adjuvant
- (2016) Kayoko Waki et al. CANCER SCIENCE
- Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma
- (2016) Daoxiang Zhang et al. CLINICAL CANCER RESEARCH
- Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle–Invasive Bladder Cancer Patients
- (2016) Laurent Derré et al. CLINICAL CANCER RESEARCH
- TLR4 Signaling via NANOG Cooperates With STAT3 to Activate Twist1 and Promote Formation of Tumor-Initiating Stem-Like Cells in Livers of Mice
- (2016) Dinesh Babu Uthaya Kumar et al. GASTROENTEROLOGY
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Johan F Vansteenkiste et al. LANCET ONCOLOGY
- Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas
- (2016) Ian F. Pollack et al. NEURO-ONCOLOGY
- Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells
- (2016) Shu Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-κB signaling pathway in non-small cell lung cancer cells
- (2016) Xue Chen et al. OncoTargets and Therapy
- Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
- (2016) Michal Lotem et al. Journal of Immunology Research
- Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma
- (2016) Katy Mastorci et al. PLoS One
- Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma
- (2015) A. H. Rook et al. BLOOD
- Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma
- (2015) Wen-Ting Liu et al. CANCER LETTERS
- Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer
- (2015) Tom J.H. Arends et al. Clinical Genitourinary Cancer
- Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation
- (2015) E. Fonte et al. HAEMATOLOGICA
- TLR Signaling Modulates Side Effects of Anticancer Therapy in the Small Intestine
- (2015) Magdalena Frank et al. JOURNAL OF IMMUNOLOGY
- Activation of Toll-like receptor 7 regulates the expression of IFN-λ1, p53, PTEN, VEGF, TIMP-1 and MMP-9 in pancreatic cancer cells
- (2015) FANG WANG et al. Molecular Medicine Reports
- MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs
- (2015) Rachid Ammi et al. PHARMACOLOGY & THERAPEUTICS
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- CpG oligodeoxyribonucleotide 7909 enhances radiosensitivity via downregulating Oct-4 expression in radioresistant lung cancer cells
- (2015) Na Xing et al. OncoTargets and Therapy
- Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation
- (2015) E. Fonte et al. HAEMATOLOGICA
- Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma
- (2015) R. L. Sabado et al. Cancer Immunology Research
- Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases
- (2015) Joseph Cannova et al. Frontiers of Medicine
- Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
- (2015) Kristina Iribarren et al. OncoImmunology
- Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice
- (2015) Bojidar M. Kojouharov et al. Oncotarget
- TLR9 Is Critical for Glioma Stem Cell Maintenance and Targeting
- (2014) A. Herrmann et al. CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence
- (2014) J. Ye et al. EMBO Molecular Medicine
- Vaccine adjuvant uses of poly-IC and derivatives
- (2014) Karen AO Martins et al. Expert Review of Vaccines
- Cancer vaccine adjuvants – recent clinical progress and future perspectives
- (2014) Abid H. Banday et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growthin vivo
- (2014) Guido Gambara et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant
- (2014) S. Adams et al. JOURNAL OF IMMUNOLOGY
- Toll-like receptors -4 and -5 in oral and cutaneous squamous cell carcinomas
- (2014) Abdirisak Ahmed Haji Omar et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Toll-Like Receptor (TLR)-1/2 Triggering of Multiple Myeloma Cells Modulates Their Adhesion to Bone Marrow Stromal Cells and Enhances Bortezomib-Induced Apoptosis
- (2014) Jahangir Abdi et al. PLoS One
- Toll-Like Receptor 4 Prompts Human Breast Cancer Cells Invasiveness via Lipopolysaccharide Stimulation and Is Overexpressed in Patients with Lymph Node Metastasis
- (2014) Huan Yang et al. PLoS One
- PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2014) H. Wimberly et al. Cancer Immunology Research
- Chronic Inflammation and Cytokines in the Tumor Microenvironment
- (2014) Glauben Landskron et al. Journal of Immunology Research
- TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells
- (2013) Hongliang Fang et al. Cellular & Molecular Immunology
- Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG
- (2013) Maurizio Brausi et al. EUROPEAN UROLOGY
- Toll-like receptor 4 activity protects against hepatocellular tumorigenesis and progression by regulating expression of DNA repair protein Ku70 in mice
- (2013) Ziyan Wang et al. HEPATOLOGY
- Pathogen Recognition Receptors: Ligands and Signaling Pathways by Toll-Like Receptors
- (2013) Miwa Sasai et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells
- (2013) Chia-Lin Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Cytokine patterns in patients with cancer: a systematic review
- (2013) Bodo E Lippitz LANCET ONCOLOGY
- Toll-like receptors in urothelial cells—targets for cancer immunotherapy
- (2013) Hélène LaRue et al. Nature Reviews Urology
- The Yin and Yang of Toll-like receptors in cancer
- (2013) J-P Pradere et al. ONCOGENE
- The Role of TLR2, TLR4 and CD14 Genetic Polymorphisms in Gastric Carcinogenesis: A Case-Control Study and Meta-Analysis
- (2013) Natalia Castaño-Rodríguez et al. PLoS One
- Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist
- (2013) L. G. Burdelya et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense
- (2012) Shaherin Basith et al. ARCHIVES OF PHARMACAL RESEARCH
- Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer
- (2012) S. Adams et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment--Poor Prognosis or New Therapeutic Opportunity
- (2012) L. A. Ridnour et al. CLINICAL CANCER RESEARCH
- Resiquimod, a topical drug for viral skin lesions and skin cancer
- (2012) Thomas Meyer et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines
- (2012) Carl R Alving et al. Expert Review of Vaccines
- Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells
- (2012) Barbara Drobits et al. JOURNAL OF CLINICAL INVESTIGATION
- Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion
- (2012) Huan Yang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Gene Silencing of Toll-Like Receptor 2 Inhibits Proliferation of Human Liver Cancer Cells and Secretion of Inflammatory Cytokines
- (2012) Yuzheng Huang et al. PLoS One
- TLR-4 Signalling Accelerates Colon Cancer Cell Adhesion via NF-κB Mediated Transcriptional Up-Regulation of Nox-1
- (2012) D. Peter O'Leary et al. PLoS One
- Targeting pattern recognition receptors in cancer immunotherapy
- (2012) Nadège Goutagny et al. Targeted Oncology
- Mycobacterium indicus pranii mediates macrophage activation through TLR2 and NOD2 in a MyD88 dependent manner
- (2012) Rajeev Kumar Pandey et al. VACCINE
- Activation of Toll-like Receptor 5 on Breast Cancer Cells by Flagellin Suppresses Cell Proliferation and Tumor Growth
- (2011) Z. Cai et al. CANCER RESEARCH
- Infectious Diseases in Patients with IRAK-4, MyD88, NEMO, or I B Deficiency
- (2011) C. Picard et al. CLINICAL MICROBIOLOGY REVIEWS
- Immunotherapeutic efficacy of Mycobacterium indicus pranii in eliciting anti-tumor T cell responses: Critical roles of IFNγ
- (2011) Srabanti Rakshit et al. INTERNATIONAL JOURNAL OF CANCER
- Toll-like Receptor 5 Agonist Protects Mice From Dermatitis and Oral Mucositis Caused by Local Radiation: Implications for Head-and-Neck Cancer Radiotherapy
- (2011) Lyudmila G. Burdelya et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines
- (2011) Cheryl Lai-Lai Chiang et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia
- (2011) Clive S. Zent et al. LEUKEMIA & LYMPHOMA
- Inflammation meets cancer, with NF-κB as the matchmaker
- (2011) Yinon Ben-Neriah et al. NATURE IMMUNOLOGY
- Cancer immunotherapy – revisited
- (2011) W. Joost Lesterhuis et al. NATURE REVIEWS DRUG DISCOVERY
- Toll-like receptor 3-mediated tumor invasion in head and neck cancer
- (2011) Hui-Ching Chuang et al. ORAL ONCOLOGY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- HMGB1 and RAGE in Inflammation and Cancer
- (2010) Gary P. Sims et al. Annual Review of Immunology
- High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer
- (2010) E L Wang et al. BRITISH JOURNAL OF CANCER
- Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma
- (2010) C. Brignole et al. CANCER RESEARCH
- Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses
- (2010) Mike D. Shelley et al. CANCER TREATMENT REVIEWS
- Toll-Like Receptors: Cost or Benefit for Cancer?
- (2010) T. Matijevic et al. CURRENT PHARMACEUTICAL DESIGN
- Death-associated protein kinase is essential for the survival of various types of uterine cancer cells
- (2010) Tanaka INTERNATIONAL JOURNAL OF ONCOLOGY
- Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance
- (2010) Julien Cherfils-Vicini et al. JOURNAL OF CLINICAL INVESTIGATION
- A Critical Role for Mast Cells and Mast Cell-Derived IL-6 in TLR2-Mediated Inhibition of Tumor Growth
- (2010) S. A. Oldford et al. JOURNAL OF IMMUNOLOGY
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
- (2010) Youn H. Kim et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker
- (2010) Rosaria Cammarota et al. Journal of Translational Medicine
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- Targeting Toll-like receptors: emerging therapeutics?
- (2010) Elizabeth J. Hennessy et al. NATURE REVIEWS DRUG DISCOVERY
- A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma
- (2010) M. R. Rosenfeld et al. NEURO-ONCOLOGY
- Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9
- (2009) A H Elmaagacli et al. BONE MARROW TRANSPLANTATION
- A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth
- (2009) Tomoe Higuchi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Triggering of Toll-like Receptor 4 Expressed on Human Head and Neck Squamous Cell Carcinoma Promotes Tumor Development and Protects the Tumor from Immune Attack
- (2009) M. J. Szczepanski et al. CANCER RESEARCH
- Toll-like receptor agonists in cancer therapy
- (2009) Sylvia Adams Immunotherapy
- Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
- (2009) Sunhwa Kim et al. NATURE
- TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection
- (2008) P. A. Taylor et al. BLOOD
- Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk
- (2008) Victoria L. Stevens et al. INTERNATIONAL JOURNAL OF CANCER
- Toll-like receptors, wound healing, and carcinogenesis
- (2008) Johannes Kluwe et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
- (2008) A M Krieg ONCOGENE
- An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models
- (2008) L. G. Burdelya et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started